http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019054891-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0314922efadd540a40d70ff927be180f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6903
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-45
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
filingDate 2018-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2f26952f5f8914e58002092570a2d8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c010af32f07a4c8c7808c81a45f2b70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f462e6ab9529e781036e5c058bf5d1e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea39256d73c83787ccecd9324ef44cc9
publicationDate 2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2019054891-A3
titleOfInvention Trpv2 antagonists
abstract This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2). Methods of treatment of conditions that are characterised by TRPV2 expression using Piperlongumine compounds and Piperlongumine compounds for use in such treatments are provided
priorityDate 2017-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3156497-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009114126-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9Y5S1
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID637858
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9WUD2
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419509932
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9WTR1

Total number of triples: 38.